As of May, 18 Analysts See $-0.08 EPS for Biofrontera AG (BFRA)

May 17, 2018 - By Andrea Pope

Earnings report for Biofrontera AG (NASDAQ:BFRA) is expected on May, 18., according to RTT. Last quarter $-0.09 earnings per share was reported. Analysts sees -11.11 % EPS growth this quarter. BFRA is reaching $13.67 during the last trading session, after increased 0.44%.Biofrontera AG has 7,736 shares volume, 17.21% up from normal. BFRA is and has moved 0.00% since May 17, 2017. The stock underperformed the S&P 500 by 11.55%.

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin.The company has $298.10 million market cap. The Company’s products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, atopic dermatitis, or psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp's natural balance; Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities; belixos To Go for relief from itchiness, insect bites, and minor burns; and Belixos PROTECT for the needs of sun-damaged skin.Last it reported negative earnings. The firm is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis.

Another two news for Biofrontera AG (NASDAQ:BFRA) were briefly brought out by: on April 30, 2018 with title “Biofrontera Reports Full Year 2017 Financial Results”. The other‘s article was titled “Pharmaceutical Update: Q1 in Review” and brought out on April 24, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: